Top

Published in:

01-05-2016 | Original Article

Seed loss in prostate brachytherapy

Operator dependency and impact on dosimetry

Authors: Nancy El-Bared, M.D., Natanel Sebbag, Dominic Béliveau-Nadeau, M.Sc., Yannick Hervieux, M.Sc., Renée Larouche, M.Sc., Daniel Taussky, M.D., Guila Delouya, M.D., M.Sc.

Published in: Strahlentherapie und Onkologie | Issue 5/2016

Abstract

Introduction

The aim of our study was to review seed loss and its impact on dosimetry as well as the influence of the treating physician on seed loss and dosimetry in patients treated with prostate brachytherapy using permanent loose ¹²⁵I implant.

Patients and methods

We analyzed 1087 consecutive patients treated by two physicians between July 2005 and April 2015 at a single institution. Pelvic fluoroscopic imaging was done 30 days post implant and a chest X-ray when seed loss was observed.

Results

Seed loss occurred in 19.4 % of patients: in 20.0 % of implants done by the most experienced physician and in 17.2 % by the less experienced physician (p = 0.4) and migration to the thorax occurred in 5.9 % (6.9 vs. 2.2 %, p = 0.004). The mean seed loss rate was 0.57 % [standard deviation (SD) 1.39] and the mean rate of seeds in the thorax was 0.14 % (SD 0.65). The most experienced physician had a higher mean number of seeds lost: 0.36 versus 0.25 (p = 0.055), and a higher mean number of seed migration to the thorax: 0.1 versus 0.02 (p < 0.001). When at least one seed was lost, a decrease of 4.2 Gy (p < 0.001) in the D90 and a decrease of 3.5 % (p = 0.002) in the V150 was observed.

Conclusion

We found a significant decrease in V150 and D90 with the occurrence of seed loss. Furthermore, we found a difference in seed migration among the physicians demonstrating that seed loss is operator dependant.

Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S et al (2011) Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol 6:130CrossRefPubMedPubMedCentral

Kono Y, Kubota K, Aruga T, Ishibashi A, Morooka M, Ito K et al (2010) Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jpn J Clin Oncol 40:1159–1165CrossRefPubMed

Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP (2006) Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 5:262–265CrossRefPubMed

Chen WC, Katcher J, Nunez C, Tirgan AM, Ellis RJ (2012) Radioactive seed migration after transperineal interstitial prostate brachytherapy and associated development of small-cell lung cancer. Brachytherapy 11:354–358CrossRefPubMed

Knaup C, Mavroidis P, Esquivel C, Stathakis S, Swanson G, Baltas D et al (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39:3291–3298CrossRefPubMedPubMedCentral

Beaulieu L, Archambault L, Aubin S, Oral E, Taschereau R, Pouliot J (2004) The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 58:1298–308CrossRefPubMed

Gao M, Wang JZ, Nag S, Gupta N (2007) Effects of seed migration on post-implant dosimetry of prostate brachytherapy. Med Phys 34:471–480CrossRefPubMed

Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ (2004) Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy 3:71–77CrossRefPubMed

Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S et al (1998) Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 42:1063–1067CrossRefPubMed

10.

Fuller DB, Koziol JA, Feng AC (2004) Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy 3:10–19CrossRefPubMed

11.

Hathout L, Donath D, Moumdjian C, Tetreault-Laflamme A, Larouche R, Beliveau-Nadeau D et al (2011) Analysis of seed loss and pulmonary seed migration in patients treated with virtual needle guidance and robotic seed delivery. Am J Clin Oncol 34:449–453CrossRefPubMed

12.

Taussky D, Moumdjian C, Larouche R, Beliveau-Nadeau D, Boudreau C, Hervieux Y et al (2012) Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy 11:452–456CrossRefPubMed

13.

Bowes D, Gaztanaga M, Araujo C, Kim D, Parker B, Batchelar D et al (2013) A randomized trial comparing seed displacement of coated seeds to regular loose seeds at 30 days postimplant. Brachytherapy 12:362–367CrossRefPubMed

14.

Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K et al (2014) A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Int J Radiat Oncol Biol Phys 90:134–9CrossRefPubMed

15.

Zuber S, Weiss S, Baaske D, Schope M, Stevens S, Bodis S et al (2015) Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. Radiat Oncol 10:49CrossRefPubMedPubMedCentral

16.

Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM et al (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79:335–41CrossRefPubMed

17.

Shiraishi Y, Yorozu A, Ohashi T, Toya K, Saito S, Nishiyama T et al (2014) A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 90:1069–75CrossRefPubMed

18.

Gacci M, Serni S, Lapini A, Vittori G, Vignolini G, Nesi G et al (2008) PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy. Prostate Cancer Prostatic Dis 11:99–101CrossRefPubMed

19.

Nag S, Demanes DJ, Hagan M, Rivard MJ, Thomadsen BR, Welsh JS et al (2011) Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: a report from the American Society for Radiation Oncology. Pract Radiat Oncol 1:218–223CrossRefPubMedPubMedCentral

Title: Seed loss in prostate brachytherapy
Operator dependency and impact on dosimetry
Authors: Nancy El-Bared, M.D.
Natanel Sebbag
Dominic Béliveau-Nadeau, M.Sc.
Yannick Hervieux, M.Sc.
Renée Larouche, M.Sc.
Daniel Taussky, M.D.
Guila Delouya, M.D., M.Sc.
Publication date: 01-05-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 5/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0961-4

At a glance: The STEP trials

Springer Medicine

Seed loss in prostate brachytherapy

Operator dependency and impact on dosimetry

Abstract

Introduction

Patients and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

Adenosine can thwart antitumor immune responses elicited by radiotherapy

Towards clinical implementation of ultrafast combined kV-MV CBCT for IGRT of lung cancer

Ist beim diffus großzelligen B‑Zell-Lymphom im frühen Stadium nach der Chemotherapie eine konsolidierende Strahlentherapie erforderlich?

Radiation recall dermatitis induced by sorafenib

Treatment of breast cancer with simultaneous integrated boost in hybrid plan technique

Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy